Aurinia Pharmaceuticals Soars 10.64% on LUPKYNIS Success

Aurinia Pharmaceuticals Inc. (AUPH) reported a 10.64% increase in pre-market trading on May 23, 2025, driven by positive news surrounding its flagship product, LUPKYNIS.

Aurinia Pharmaceuticals Inc. reported a 24% increase in total revenue for Q1 2025, reaching $62.5 million compared to $50.3 million in Q1 2024. This significant revenue growth underscores the company's strong financial performance and market position.

New findings from a post-hoc analysis of the Phase 3 AURORA 1 study demonstrated that lupus nephritis patients receiving triple immunosuppressive therapy with LUPKYNIS achieved significantly lower proteinuria levels compared to the control group. This suggests that LUPKYNIS-based therapy could lead to better long-term kidney health and reduced cardiovascular risk for patients, reinforcing its critical role in improving health outcomes for lupus nephritis patients.

The positive data from the AURORA 1 study, presented at LUPUS 2025, further underscores the potential of LUPKYNIS in improving kidney health outcomes for lupus nephritis patients. The findings highlight the superior efficacy of LUPKYNIS in treating this severe autoimmune disease, which could drive further investor confidence in the company's prospects.